F18 - Tips and Tricks for Using CGM in Pregnancy

Friday, August 8, 2025

2:30 PM – 3:15 PM MT

CE/CME Hours: .75 CE

Pharmacology Hours: .25 CE

Primary Presenter(s)

Diana Isaacs, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM (she/her/hers)

Endocrine Pharmacist
Cleveland Clinic
University Heights, Ohio

Disclosure(s): Abbott: Speakers' Bureau (Ongoing); Dexcom: Speakers' Bureau (Ongoing); Insulet: Speakers' Bureau (Ongoing); Lilly: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Speakers' Bureau (Ongoing); Sanofi: Speakers' Bureau (Ongoing); Sequel: Consultant / Advisory Board (Ongoing)

Co-Presenter(s)

LH

Logan Hunkus, PharmD

Endocrine Clinical Pharmacy Specialist
Cleveland Clinic
Youngstown, Ohio

Disclosure(s): No financial relationships to disclose

Glycemic targets are more intensive during pregnancy to prevent maternal and neonatal complications. Now with FDA approved CGM devices in pregnancy, use has increased dramatically in both gestational and pregestational diabetes. This session reviews the latest guidelines, clinical trials and best practices for use of CGM in pregnancy. The presenters showcase several cases demonstrating how to utilize CGM data to optimize lifestyle, behaviors, and medications to achieve glycemic targets in pregnancy.

Disclosure(s):

Diana Isaacs, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM: Abbott: Speakers' Bureau (Ongoing); Dexcom: Speakers' Bureau (Ongoing); Insulet: Speakers' Bureau (Ongoing); Lilly: Speakers' Bureau (Ongoing); Medtronic: Consultant / Advisory Board (Ongoing); Novo Nordisk: Speakers' Bureau (Ongoing); Sanofi: Speakers' Bureau (Ongoing); Sequel: Consultant / Advisory Board (Ongoing)

Logan Hunkus, PharmD: No financial relationships to disclose